Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303. Oncotarget. 2015. PMID: 26056084 Free PMC article.
Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination.
Pascual-Pasto G, Olaciregui NG, Vila-Ubach M, Paco S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacis M, Catala J, Salvador H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Cancer Lett. 2016 Sep 28;380(1):10-9. doi: 10.1016/j.canlet.2016.06.012. Epub 2016 Jun 16. Cancer Lett. 2016. PMID: 27319373
Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NKV, Mora J, Sosnik A, Carcaboso AM. Monterrubio C, et al. J Control Release. 2017 Jun 10;255:108-119. doi: 10.1016/j.jconrel.2017.04.016. Epub 2017 Apr 12. J Control Release. 2017. PMID: 28412222 Free PMC article.
Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier.
Pascual-Pasto G, Olaciregui NG, Opezzo JAW, Castillo-Ecija H, Cuadrado-Vilanova M, Paco S, Rivero EM, Vila-Ubach M, Restrepo-Perdomo CA, Torrebadell M, Suñol M, Schaiquevich P, Mora J, Bramuglia GF, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Among authors: vila ubach m. J Control Release. 2017 Oct 28;264:34-44. doi: 10.1016/j.jconrel.2017.08.018. Epub 2017 Aug 19. J Control Release. 2017. PMID: 28830790
Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas.
Bukchin A, Pascual-Pasto G, Cuadrado-Vilanova M, Castillo-Ecija H, Monterrubio C, Olaciregui NG, Vila-Ubach M, Ordeix L, Mora J, Carcaboso AM, Sosnik A. Bukchin A, et al. Among authors: vila ubach m. J Control Release. 2018 Apr 28;276:59-71. doi: 10.1016/j.jconrel.2018.02.034. Epub 2018 Feb 28. J Control Release. 2018. PMID: 29501533
The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.
García-Domínguez DJ, Hontecillas-Prieto L, Rodríguez-Núñez P, Pascual-Pasto G, Vila-Ubach M, García-Mejías R, Robles MJ, Tirado OM, Mora J, Carcaboso AM, de Álava E. García-Domínguez DJ, et al. Among authors: vila ubach m. Oncotarget. 2018 Jul 31;9(59):31397-31410. doi: 10.18632/oncotarget.25829. eCollection 2018 Jul 31. Oncotarget. 2018. PMID: 30140378 Free PMC article.
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.
Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, Carmen de T, Fu L, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Among authors: vila ubach m. Sci Transl Med. 2019 Jan 23;11(476):eaat9321. doi: 10.1126/scitranslmed.aat9321. Sci Transl Med. 2019. PMID: 30674657 Clinical Trial.
Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.
Castillo-Ecija H, Monterrubio C, Pascual-Pasto G, Gomez-Gonzalez S, Garcia-Dominguez DJ, Hontecillas-Prieto L, Resa-Pares C, Burgueño V, Paco S, Olaciregui NG, Vila-Ubach M, Restrepo-Perdomo C, Cuadrado-Vilanova M, Balaguer-Lluna L, Perez-Jaume S, Castañeda A, Santa-Maria V, Roldan M, Suñol M, de Alava E, Mora J, Lavarino C, Carcaboso AM. Castillo-Ecija H, et al. Among authors: vila ubach m. J Control Release. 2020 Aug 10;324:440-449. doi: 10.1016/j.jconrel.2020.05.032. Epub 2020 Jun 1. J Control Release. 2020. PMID: 32497782
19 results